Study and trials of vaccines for leukemia

According to the prestigious scientific publisher ScienceDirect, in an article published on July 10, 2025, great progress is being made in the study of vaccines targeting the cancer cells that cause leukemia. This article and its images are based on information from that scientific publication on ScienceDirect.

Because not everyone understands more than one language, we are including a translation of the article and a link so you can consult the original source.

Let’s keep going — we will win this battle. Help us help others.

Donate and help speed up the work with One Shôt. As you can see, these processes are slow, but with funding we can accelerate them.

“Therapeutic vaccines offer a potential definitive cure for cancers, including leukemia. Although personalized vaccines based on neoantigens show clinical benefits, they are limited by long and delicate manufacturing procedures, high costs, and possibly incomplete coverage of heterogeneous tumor cells. Here, we present a simple strategy to generate powerful in situ therapeutic vaccines that effectively eliminate leukemia and induce long-term anti-leukemia immunity through homoharringtonine–nano-dual-adjuvant (HHT-NDA) therapy. HHT effectively kills leukemia cells and produces abundant tumor antigens by inducing immunogenic cell death. NDAs work together to promote the maturation and antigen presentation of dendritic cells by activating both nucleotide-binding oligomerization domain-containing protein 2 (NOD2) and toll-like receptor 9 (TLR9). HHT-NDA treatment in a mouse model of MLL-AF9 acute myeloid leukemia leads to 57–71% complete regression and 100% protection against rechallenge, in line with the expansion of memory CD8+ T cells. This standard-of-care chemotherapy, combined with the nano-dual-adjuvant, offers a novel strategy for generating in situ therapeutic vaccines for leukemia.”

https://www.sciencedirect.com/science/article/abs/pii/S0168365925004717

We are The IMpatients.

ForyP.